Pershing Square backs Alcon as analysts see 13.3% upside
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Pershing Square has given a positive assessment of Alcon, calling it a high-quality eye-care company with strong earnings growth potential, citing raised guidance and a compressed earnings multiple. Alcon reports third-quarter results on November 10. Analysts carry a mean target of $81.98 versus a $72.37 price, implying 13.3% upside, with ratings at 21 Buy, 5 Hold and 1 Sell.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.